TWIN WIN ZERTIFIKAT - BIONTECH ADR Share Price

Certificat

DE000HVB6309

Delayed Deutsche Boerse AG 10:34:36 23/05/2024 pm IST
305.5 EUR +13.41% Intraday chart for TWIN WIN ZERTIFIKAT - BIONTECH ADR
Current month+1.89%
1 month+2.20%
Date Price Change
23/24/23 305.5 +13.41%
22/24/22 269.4 -0.29%
21/24/21 270.2 -1.19%
20/24/20 273.4 +0.15%
17/24/17 273 -0.76%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 10:34 pm IST

More quotes

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer UniCredit UniCredit
WKN HVB630
ISINDE000HVB6309
Date issued 07/12/2021
Maturity 02/12/2024 (193 Days)
Parity 0.34 : 1
Emission price 1,000
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1,010
Lowest since issue 252.7
Spread 3.08
Spread %1.00%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
94.41 EUR
Average target price
104.7 EUR
Spread / Average Target
+10.92%
Consensus